SLC5A2 and aortic valve stenosis: Emerging preclinical and clinical evidence suggests that these benefits may extend to patients with AS, where myocardial SGLT2 expression has been implicated in the pathogenesis of fibrosis, inflammation, oxidative stress, and metabolic dysfunction [28,29,30].